[Frontiers in Bioscience S4, 1201-1212, June 1, 2012]
Proteinase-activated receptors in the endometrium and endometriosis
Yutaka Osuga1, Yasushi Hirota1, Osamu Yoshino1, Tetsuya Hirata1, Kaori Koga1, Yuji Taketani1
1
TABLE OF CONTENTS
1. ABSTRACT
Proteinase-activated receptors (PARs) are G protein-coupled receptors activated by various proteinases. PARs play important roles in haemostasis, thrombosis, and inflammation. PAR1 and PAR2 are expressed in endometrial cells from the eutopic endometrium and endometriotic cells derived from endometriotic lesions. A typical activator of PAR1, thrombin, and a typical activator of PAR2, tryptase, are produced in the endometrium as well as endometriotic lesions. PAR1 activation in endometrial stromal cells induces production of vascular endothelial growth factor and matrix metalloproteinases, and increases activities of tissue-type and urokinase-type plasminogen activator. PAR2 activation in endometrial stromal cells stimulates interleukin (IL)-8 and stem cell factor production and proliferation of the cells. PAR1 activation in endometriotic stromal cells induces production of IL-8, monocyte chemotactic protein-1, and cyclooxygenase-2, and proliferation of the cells. PAR2 activation in endometriotic stromal cells increases secretion of IL-6 and IL-8, and the number of the cells. These findings indicate a wide range of function of PAR1 and PAR2 in the endometrium and endometriosis, and suggest PAR1 and PAR2 as possible therapeutic targets for endometriosis.
2. PROTEINASE-ACTIVATED RECEPTORS: OVERVIEW
The family of proteinase-activated receptors (PARs) is comprised of four members: PAR1, PAR2, PAR3 and PAR4. PARs are G protein-coupled receptors (GPCRs) that are uniquely activated by proteinases. PARs are expressed in various cells including vascular, immune and epithelial cells, astrocytes and neurons and transmit cellular responses to coagulant proteinases as well as other proteinases expressed in distinct tissues (1-4). PARs are critical mediators of haemostasis, thrombosis, inflammation, and have been implicated in cancer progression, indicating this receptor class as an important drug target.
Activation of PARs is induced through an irreversible proteolytic mechanism. Proteinases bind to and cleave the extracellular N-terminal domain of PARs at specific sites to unmask a new N-terminus that acts as a tethered ligand that binds to the receptor and triggers intracellular signaling (Figure 1). Synthetic peptides that mimic the first six amino acids of the newly formed N-terminus can activate PARs independent of proteinase and receptor cleavage, except for PAR3(5). Viewed more closely, the activation of PARs is thought to occur through peptide ligand interactions with residues residing in the second extracellular loop (6), unlike most classic GPCRs where ligand binding occurs in a pocket formed by the transmembrane helices. Once activated, GPCRs function as guanine nucleotide exchange factors and promote exchange of GDP for GTP on the α subunit leading to βγ subunit dissociation. Both the GTP bound α subunit and βγ subunits signal to various effectors to promote diverse cellular responses. Activated PARs also interact with various adaptor proteins, such as β-arrestins, that facilitate signal transduction independent of heterotrimeric G protein coupling(5). Activation of PARs also induces the activation of mitogen-activated protein kinases (MAPKs), including extracellular signal-regulated kinases (ERK1/2), c-Jun N-terminal kinases (JNKs) also known as stress-activated protein kinases (SAPKs), and p38 MAPK (7, 8).
Proteinases that cleave and activate PARs are various, including proteinasesfrom the coagulation cascade, inflammatory cells, and the digestivetract. Serine proteinases of the coagulation cascade are thebest characterized activators of PARs (9, 10). Proteinases that mediate coagulation and anticoagulationby cleaving zymogens or active enzymes themselves can also signalto several cell types by cleaving and activating PARs. Thrombin activates PAR1, PAR3, or PAR4 at the surface of platelets,resulting in aggregation, which contributes to hemostasis (9).Tissue factor (TF)-VIIa complex and TF-VIIa-Xa complex signal by cleaving PAR1 and PAR2 ona range of cell types, including endothelial cells, playing an important role in inflammation (11-13).
Mast cell tryptase has been noted asan activator of PAR2. Tryptase is the most abundant proteinaseof human mast cells; it comprises up to 25% of the total cellularproteins and is expressed by almost all subsets of human mastcells (14). Many of the proinflammatory and mitogenic effectsof tryptase are mimicked by PAR2 agonist peptides (APs), suggesting that tryptaseexerts its effects through this receptor. Human tryptase from a varietyof sources (purified from human lung, skin, and mast cell lines)can cleave PAR2 to expose the tethered ligand domain and signalsto PAR2 transfected cells as well as many cell types that naturallyexpress PAR2 at physiological levels(4).
3. PROTEINASE-ACTIVATED RECEPTORS IN THE ENDOMETRIUM
3.1. Role of proteinase-activated receptor 1 in the endometrium
The human endometrium is a dynamic tissue that, in responseto the prevailing steroid environment of sequential ovarianestrogen and progesterone exposure, undergoes well-characterizedcycles of proliferation, differentiation, and tissue breakdownon a monthly basis. If pregnancy fails to be established, the endometrium is thenshed and regenerates. Menstruation is thereproductive process whereby the upper two thirds of the endometriumis shed and regenerated repeatedly.The endometrium is accordingly a site of recurrent physiologicalinjury and repair (15). The remodelling of the endometrium occur naturally not only menstruation but also parturition, endometrial regeneration and uterine involution and have features in common with events of tissue injury and repair in other tissues, where many proteinases play important roles.
Decidualization of human endometrial stromal cells is initiated in the midluteal phaseand spreads throughout the late luteal phase endometrium.Decidualized cells express high levels of TF (16-18), whichbinds to plasma factors VII/VIIa to generate factor Xa. Theresulting formation of thrombin from prothrombin initiates hemostasisby converting fibrinogen to fibrin. Moreover, thrombinmediates various cellular effects by binding to a family ofPARs. The luteal phase is accompaniedby increased vascular permeability and stromal edema, whichwould generate thrombin via enhanced access of circulating plasmaclotting factors to TF derived from perivascular decidual cell. It is thus feasible that thrombin play a role in the decidualized endometrium.
Throughout the menstrual cycle, angiogenesis is tremendously significant process to support the function and the architecture of the endometrium(19, 20). In nonfertile menstrual cycles, progesterone withdrawal appearsto elicit ischemia, hypoxia, and endometrial sloughing. After that, ruptured endometrial spiral arteriolesand venules are suggested to serve as an angiogenic nidus that restores the vasculaturein the next cycle. According to this notion, endothelial cellssprout from the disrupted vessels and recruit or induce pericytesor smooth muscle cells to form capillaries, venules, or arterioles. However, the mechanisms that contribute to post-menstrual repair and secretory phase remodelling have not clearly understood while stereological data has identified vessel elongation as a major endometrial angiogenic mechanism in the mid-late proliferative phase(20). From the molecular point of view, angiogenic factors identifiedin human endometrium includes epidermal growth factor,fibroblast growth factor, platelet-derived growth factor,and TGF-ß, angiopoietin and VEGF, and VEGF is noted as the mostlikely mediator of endometrial angiogenesis (19, 21, 22).
VEGF expression is induced by thrombin in several celltypes (23-25). Thrombin induces VEGF secretion from human endometrial stromal cells that are decidualized by estradiol and medroxyprogesterone acetate. In addition, a synthetic thrombin receptor activating peptide stimulates PAR1 to increase VEGF secretion in decidualized human endometrial stromal cells (26). These findings indicate that thrombin mediates angiogenesisindirectly by enhancing VEGF expression in human endometrial stromal cells. Interestingly, thrombinalso stimulate angiogenesis directly by enhancingendothelial proliferation and by elevating levels of the KDRreceptor in endothelial cells (27). Collectively, decidual cell-derived thrombin and VEGF may act via their respectivereceptors to synergistically enhance luteal phase angiogenesis.Moreover, thrombin and VEGF each enhance endothelial permeabilityby different pathways (28, 29). This would increase access ofclotting factors to decidual cell-expressed TF to promote a feed-forwardcycle of enhanced thrombin and VEGF production. These findings appear to be consistent with the persistence of angiogenesis, as wellas the peak in VEGF expression in the luteal phase endometrium.
Thrombin may play not only physiological but pathological roles in the endometrium. For example, thrombin may elicit abnormal uterine bleeding by promoting aberrantangiogenesis and/or vessel maintenance. In contrast to ovariansteroid withdrawal-mediated menstrual bleeding, the chronic, erratic, and prolongedbleeding occurs from compromised surface microvessels in users of long-term progestin-only contraception(21). The endometrium from such patients show increased expression of TF (18, 30) as well as of VEGF (31). As VEGF would elicit a prolongedincrease in vascular permeability, chronic TF-derivedthrombin generation may further stimulates VEGF production with resultant sustaining aberrant angiogenesis.Aberrant angiogenesis would produce the enlarged, distended, fragile vesselsand overcomes TF-thrombin mediated hemostasis.
Extracellular matrix degradation is also essential for the regulation of angiogenesis (32). This process is controlled by several enzymes, specifically by a family of matrix metalloproteinases (MMPs), which possess a zinc molecule at their catalytic site and are divided into three subclasses according to their substrate specificity (33, 34). Thrombin and a PAR1 agonist SFLLRN increase the production of MMP-1 and active MMP-2 from cultured secretory phase endometrial stromal cells. The increase is suppressed by an MEK inhibitor, suggesting that thrombin stimulates the production of MMPs via activation of PAR1 and the MAPK system. In order to stimulate angiogenesis and sustain integrity of the endometrium, PAR1 activation by thrombin may coordinate vessel growth and tissue degradation via the production of VEGF and MMPs.
PAR1 also plays an important role in lysis of blood clots, which is an essential phenomenon to maintain the homeostasis of the endometrium where both physiological and pathological bleeding occurs. Tissue-type plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA) are serine proteinases involved in the breakdown of blood clots. As an enzyme, it catalyzes the conversion of plasminogen to plasmin, the major enzyme responsible for clot breakdown. Plasminogen activator inhibitor (PAI-1) inhibits the serine proteinases tPA and uPA, and hence inhibits fibrinolysis, the process that degrades blood clots (35). Thrombin, by activating PAR1, stimulates the secretion of uPA, tPA, and PAI-1 in cultured endometrial stromal cells. This might be somewhat complicated in that both agonistic and antagonistic substances for plasminogen activating system are upregulated. However, the consequent net activity induced by thrombin is the increase in tPA and uPA activity (36). Progesterone works towards the adverse direction, suppressing uPA and tPA activitiy by increasing the production of PAI-1 and decreasing the production of uPA and tPA in endometrial stromal cells (17, 37). Given these findings, perivascular decidualized stromal cells may modulate the conflicting requirements for hemostasis during placentation and hemorrhage during menstruation. In the midluteal phase, stroma edema and transudation of plasma proteins are expected to facilitate thrombin generation at perivascular sites. However, a high progestational miliu would minimize thrombin enhancement of PA activity and may support implantation of the blastocyst. In contrast, the reduction of circulating progesterone that occurs at the end of the luteal phase impedes this effect and increase thrombin enhancement of PA activity. As a result, the increased PA activity would promote fibrinolysis and endometrial stromal ECM degradation, facilitating the sloughing of the functional layer of the endometrium.
3.2. Role of proteinase-activated receptor 2 in the endometrium
PAR2 as well as PAR1 play various roles in the endometrium during the menstrual phase. As described above, decidualized endometrial cells express high levels of TF, whichbinds to plasma factors VII/VIIa to generate factor Xa. TF-VIIa complex and TF-VIIa-Xa complex are produced in this process and function as an activator of PAR2. Mast cell tryptase also activates PAR2 in the endometrium. It is well known that a variety of lymphomyeloid cells are present in the endometrium and modulate the endometrial functions (15). Mast cells do not alter in number during the cycle, but dramatic mast cell activation occurs immediately before and during menstruation. Extensive mast cell activation/degranulation, as judged by extracellular tryptase, was a common feature of the functional layer of the endometrium just prior to and during menstruation(38). It is thus plausible that PAR2 is highly activated by TF-VIIa complex, TF-VIIa-Xa complex, and mast cell tryptase in the decidualized endometrium around menstruation period.
Expression of PAR2 in the endometrial tissues is observed throughout the menstrual cycle andin the decidual tissues. The expression levels appear to be low from the midproliferative phase to themidsecretory phase and increase from the late secretory phaseto the early proliferative (menstrual) phase (39). The expressionlevels are also increased in the decidual tissues. This expression pattern of PAR2 seems to be in proportion to the production of TF-VIIa complex, TF-VIIa-Xa complex and tryptase in the endometrium and to be appropriate for PAR2 to exert its effects efficiently in the endometrium.
We have shown that PAR2 is expressed in endometrial stromal cells and epithelial cells, with some interindividual variation. PAR2 activation increase the production of IL-8 in both endometrial stromal and epithelial cells and the proliferation of endometrial stromal cells (39). IL-8 is a CXC chemokine produced by a range of cells. Primary function of IL-8 is the induction of chemotaxis of neutrophils. It also functions as a potent angiogenic factor. In addition, IL-8 stimulates the proliferation of several cell types, including endometrial stromal cells. Interestingly, IL-8 antisense oligonucleotide treatment decrease IL-8 production as well as cell proliferation compared with scrambled oligonucleotide treatment (40, 41), suggesting that IL-8 may act as an autocrine growth factor in the endometrium. The expression of IL-8 is low during the midproliferative to midsecretory phase and high around menstruation (42-44). It is speculated that IL-8 is responsible for leukocytes accumulation in the endometrium around the time of menstruation where leukocytes are involved in the degradation and scavenging of endometrial tissue. IL-8 in the uterus is also suggested to play unique roles in endometrial angiogenesis (45), which is crucial for appropriate repairing of the endometrium after menstruation. Moreover, IL-8 increases matrix metalloproteinases and adhesion to fibronectin in endometrial stromal cells (46-48). Given a wide variety of functions of IL-8 in the endometrium, PAR2 activation would influence the endometrial function through enhancing IL-8 expression in the endometrium.
It is notable that PAR2 activation increases the expression of stem cell factor (SCF) also known as kit-ligand (KL), or steel factor in the endometrium (39). SCF is a cytokine that is known to play an important role in hematopoiesis, spermatogenesis, and melanogenesis. With regard to PAR2 in the endometrium, functions of SCF on mast cells should be noticed. Mast cells are the only terminally differentiated hematopoietic cells that express SCF receptor. Mice with SCF mutations have severe defects in the production of mast cells, having less than 1% of the normal levels of mast cells. Conversely, the injection of SCF increases mast cell numbers near the site of injection by over 100 times. SCF also promotes mast cell adhesion, migration, proliferation, and survival. Moreover, it promotes the release of histamine and tryptase, which are involved in the allergic response (49). As mentioned above, extracellular tryptase indicative of mast cell activation and degranulation is remarkably increased in the endometrium around menstrual period (38). Given the possible significance of mast cell-derived proteinases, such as tryptase and chymase, in extracellular matrix degradation and tissue remodeling of the endometrium (50), the increase in PAR2 expression at the menstrual period may upregulate SCF production in endometrial stromal cells and consequently activate mast cells to repair the shed endometrium. It is interesting to speculate that the function of mast cells may be potentiated by SCF via the feed-forward loop comprised of tryptase, PAR2 and SCF in the endometrium.
Matrix metalloproteinase 7 (MMP-7), or matrilysin, is a secreted proteinase expressed by glandular and mucosal epithelial cells, keratinocytes, fibroblasts and macrophages (51). As with other MMPs it can act on the extracellular matrix and thereby regulate cell migration and tissue repair. MMP-7 is secreted as an inactive protein pro-MMP-7 which is converted to the active form MMP-7 when cleaved by extracellular proteinases. PAR2 activation increases MMP-7 production in endometrial epithelial cells (39). MMP-7 is expressed in the endometrium in the perimenstrual and proliferative phase but not the early to midsecretory phase (52). As this expression pattern is similar to that of PAR2, it is speculated that the PAR2 activation-induced MMP-7 production contributes to the MMP-7 expression in the endometrium. This expression pattern also implies possible roles of the enzyme in tissue breakdown and regeneration of the endometrium around the menstrual period. Accordingly, PAR2 activation in endometrial epithelial and stromal cells may be an integral event for the tissue modification to restore the disrupted endometrium during the menstrual cycle.
PAR2 activation is mediated via different sets of MAPKs, depending on the cell type (53-55). PAR2 activation stimulates the phosphorylation of ERK1/2, JNK, and p38 MAPK in endometrial stromal cells (39). This finding may explain the pleiotropic effects of PAR2 in endometrial stromal cells as the MAPK signal transduction pathways are among the most widespread mechanisms of eukaryotic cell regulation. Interestingly, inhibitors of all the three MAPKs inhibited PAR2-dependent IL-8 secretion from endometrial stromal and epithelial cells. In addition, the PAR2-induced proliferation of endometrial stromal cells is suppressed with these inhibitors. Consequently, it is suggested that all the three MAPKs are involved in the signal transduction in the endometrium.
4. PROTEINASE-ACTIVATED RECEPTORS IN ENDOMETRIOSIS
4.1. Role of proteinase-activated receptor 1 in endometriosis
Endometriosis is defined as the presence of endometrial glands and stroma outside the endometrial cavity and uterine musculature. These ectopic endometrial implants are usually located in the pelvis, but can occur nearly anywhere in the body. Endometriosis can be associated with many distressing and debilitating symptoms, such as pelvic pain, severe dysmenorrhea, and dyspareunia (56, 57). It also often causes infertility and deteriorates quality of life of women in reproductive ages. Despite numerous studies, considerable controversy remains regarding the incidence, pathogenesis, natural history, and optimal treatment of this disorder. As a pathogenesis of the disease, the implantation theory is most widely believed which proposes that endometrial tissue from the uterus is shed during menstruation and transported through the fallopian tubes, thereby gaining access to and implanting on pelvic structures (58). However, substantial molecular mechanisms that corroborate the theory have not been clearly elucidated. In addition, how the implanted endometriotic lesion grows or regresses is not well understood either.
Studies on its pathogenesis for long years suggest that endometriosis has features of a chronic inflammatory disease. For instance, elevated concentrations of proinflammatory mediators (59-62) and increased concentrations of inflammatory cells (63, 64) have been reported in the peritoneal fluid of women with endometriosis. In addition, inflammatory responses occurring in endometriotic cells are suggested to accelerate endometriosis (65-67). The inflammatory changes observed in the peritoneal cavity are assumed to be induced by endometriotic cells, local inflammatory cells (68), and secretory products such as prostaglandins(62) and proinflammatory cytokines (57, 69, 70). Proteinases activated in the coagulation cascades are also possible inducers of inflammation in endometriosis (71).
Another specific feature of endometriosis is recurrent bleeding (72). Early peritoneal lesions frequently represent one or more small endometriotic polyps emerging from glandular structures located in the subperitoneal tissue (red lesions) (73). These early lesions are highly vascularized implants and bleed at menstruation (74). The puckered, pigmented lesion is characterized by a variable amount of fibrosis, a moderately vascularized stroma, glands with intraluminal debris, and the presence of hemosiderin-laden macrophages (black lesions). Endometrial cyst is a pseudocyst likely to be formed by a hematoma that causes invagination of the ovarian cortex, and is colonized by endometriotic epithelium and stroma. On histologic examination evidence of extravasation of red blood cells or the presence of hemosiderin-laden macrophages has been found in a large proportion of biopsies of histologically verified endometriosis (75). Once bleeding occurs, hemostasis follows by activating coagulation cascade. It is thus quite feasible that endometriotic lesions are exposed to various substances produced in the coagulation process. Thrombin is one of the typical products of the process which not only catalyzes plasminogen to plasmin but stimulates PAR1.
PAR1 is expressed in endometriotic stromal cells as well as eutopic endometrial cells. Thrombin and SFLLRN increase gene expression and secretion of IL-8 and MCP-1 from endometriotic stromal cells (71). MCP-1 and IL-8 are typical chemokines involved in the pathogenesis of endometriosis. Concentrations of MCP-1 and IL-8 are increased in the peritoneal fluid of women with endometriosis (41, 76, 77). They are expressed in endometriotic lesions, and their expressions are increased with IL-1ß treatment (65, 78, 79). MCP-1, also known as CCL2, is an inflammatory cytokine belonging to the CC chemokine family, and has been implicated in the pathogenesis of diseases characterized by monocytic infiltrates, like psoriasis, rheumatoid arthritis and atherosclerosis. MCP-1 is suggested to recruit and activate macrophages in endometriosis, and these macrophages are supposed to play a central role in the pathophysiology of the disease. As observed in the eutopic endometrium, IL-8 plays pleiotropic functions in endometriotic lesions, such as chemoattraction and activation of neutrophils, angiogenesis, stimulation of proliferation, and survival of endometriotic cells, and are suggested to contribute to the development of endometriosis (80, 81). With these backgrounds, the finding that activated PAR1 stimulated productions of MCP-1 and IL-8 in endometriotic cells supports the notion that the thrombin not only plays a role in a coagulation cascade but regulates the production of significant chemokines responsible for the development of endometriosis.
Thrombin and SFLLRN induce cyclooxygenase-2 (COX-2) expression in endometriotic stromal cells, indicating the involvement of PAR1 in COX-2 expression in endometriosis (71). Prostaglandins produced by the enzyme activity of COX-2 stimulate the inflammation and promote the disease. In particular, locally produced prostaglandin E2 stimulates the expression of steroidogenic genes that enable the endometriotic stromal cells to synthesize estradiol (82), which exacerbate the disease.
PAR1 activation in endometriotic stromal cells has another remarkable feature: induction of TF expression (71). IL-8 also stimulates TF expression in endometriotic stromal cells. TF localizes initial part of extrinsic pathway of coagulation cascade and make complex with factor VIIa to activate downstream coagulation process. Taken together, a feed-forward loopto enhance inflammation and coagulation is possibly present at bleeding site of endometriosis, where PAR1 activation could link inflammationwith coagulation, and confers self-sustaining mechanismsfor the progression of endometriosis (Figure 2). PAR1 activation may also contribute to the development of endometriosis as thrombin stimulates proliferation of endometriotic stromal cells through PAR1 activation (71).
Interestingly, thrombin, butnot PAR1 agonist SFLLRN, increased the production of pro-MMP-9 and MMP-2 in endometriotic cells, indicating that this effect is independent from PAR1. This response may be mediated by thrombinbinding to thrombomodulin which increase MMP-2 production by activating protein C (83, 84). It is known that MMP-2 and MMP-9 are increased in endometriotic tissues (85, 86). Given that the increased MMPs are involved in the development of endometriosis by promoting breakdown and remodeling of endometriotic tissues, the effect of thrombin to increase the MMPs also contribute to the progression of the disease.
Assuming that thrombin activation promotes the development of endometriosis, inhibition of PAR1 is a promising therapeutic approach for the treatment of the disease. Because a PAR1 antagonist is specific for the cellular actions of thrombin and does not interfere with fibrin generation, it is expected to have less adverse effects on bleeding than the currently available thrombin inhibitors. In fact, chemicals with selective antagonistic effects on PAR1 did not perturb coagulation parameters in animal models (87, 88). Hence, it would be interesting to examine whether these substances have the potential for endometriosis therapy.
4.2. Role of proteinase-activated receptor 2 in endometriosis
Accumulating evidence supports that endometriosis has characteristics of an allergic disease in which mast cells play an essential role in allergic inflammation (89-94). High numbers of activated mast cells are present in endometriosis sites that are strongly positive for corticotropin-releasing hormone and urocortin both of which can activate mast cells (95, 96). Concentrations of SCF, which stimulates mast cells, are increased in peritoneal fluid of women with endometriosis (60). Invasions of mast cells and degranulation as well as proliferation of interstitial component have been documented in endometriotic lesions from patients with endometriosis (90, 95). In addition, a relation between endometriosis and allergy is also supported by the finding that interstitial hyperplasia, which is a major step of infiltration and lesion of mast cells, is significantly inhibited by the administration of a leukotriene (LT) antagonist that has antiallergic action in the rat endometriosis model (97-100). Collectively, endometriosis has the typical characteristics of type I allergy.
Tryptase is a representative serine proteinase released by activated mast cells in endometriotic lesion (89, 95). We demonstrated that PAR2, which is activated by mast cell-derived tryptase, is expressed in endometriotic stromal cells (7). This finding indicates possible involvement of tryptase-induced activation of PAR2 in endometriosis. PAR2 in endometriotic stromal cells may also be activated by TF-VIIa complex and TF-VIIa-Xa complex in view of the specific feature of the endometriosis, recurrent bleeding. Activation of PAR2 induces an increase in IL-6 and IL-8 secretionby endometriotic stromal cells (7). IL-8 is suggested to promote the development of endometriosis as described above. Multiple lines of evidence indicate that IL-6 is also involved in the progression of the disease (101). The expression of IL-6 is increased in both endometriotic tissue and in peritoneal fluid of women with endometriosis (102, 103). IL-6 increases aromatase activity, haptoglobin production, and hepatocyte growth factor production in endometriotic cells and/or endometriotic cells (104-107). Furthermore, IL-6 directly stimulates the proliferation of endometriotic stromal cells (104). These findings indicate that IL-6 stimulate the progression of endometriosis by various mechanisms such as cell proliferation, angiogenesis, and immunomodulation. Given the promoting roles of IL-6 and IL-8 in endometriosis, mast cell tryptase, TF-VIIa complex, and TF-VIIa-Xa complex could contribute to the development of the disease by activating PAR2 which in turn increase IL-6 and IL-8 production. Viewed in a wider framework, PAR2 appears to translate an allergic response and a coagulating response into an inflammatory response that develop the endometriosis. Another function of PAR2 is that PAR2 activation stimulates proliferation of endometriotic stromal cells (7). This also underscores the importance of PAR2 in the pathogenesis of endometriosis. Interestingly, inhibitors of ERK1/2, JNK, and p38 MAPK suppress the PAR2 activation-induced proliferation in endometriotic stromal cells (7), which is similar to the finding observed in endometrial stromal cells.
4.3 Proteinase-activated receptor 2 in mouse model of endometriosis
There are several model of endometriosis in mouse (108). We have developed an autotransplantation-type model. In this model, the uterus of donor mouse that is ovariectomized and treated with estradiol is removed and its endometrium is minced. The minced endometrium is injected using needle into the abdominal cavity of the recipient mice that is also ovariectomized and treated with estradiol. The advantage of this model is that the injected endometrium mimics the endometrium in retrograde menstruation in women. The characteristics of our method were demonstrated by the model using green fluorescent mouse and we have reported several studies using our method (109-112).
In view of the in vitro study showing the possible roles of PAR2 in the establishment of endometriosis, we performed an an in vivo study using our endometriosis model with PAR2-deficient mice (kindly provided by Kowa Co. Ltd.). As expected, both the number and the total weight of endometriotic lesions were significantly decreased in the PAR2-deficient mice compared to the wild type mice (109). At the same time, concentrations of IL-6 and MCP-1 were decreased in the peritoneal fluid and the serum of the PAR2-deficient mice. As described above, IL-6 and MCP-1 are suggested to promote endometriosis via inflammatory responses. Therefore, the decreased concentrations of IL-6 and MCP-1 in the PAR2-deficient mice imply that endometriosis-associated inflammation is alleviated in the peritoneal cavity of the mice. Collectively, PAR2 is suggested to be involved in the development of experimental endometriosis in mice and that the anti-inflammatory environment in PAR2-deficient mice might hinder the progression of the disease. Combined with the findings of the in vitro study, PAR2 would be argued as a target for the treatment of endometriosis. It is also noticed that p38 MAPK inhibitor impede the development of endometriosis in the similar mouse model (110). In light of the finding that p38 MAPK inhibitor suppress the PAR2 activation-induced proliferation of human endometriotic stromal cells, the inhibitory effect of the p38 MAPK inhibitor on endometriosis observed in the mouse model may partly dependent on the inhibition of the PAR2 function.
5. PERSPECTIVE
PAR1 and PAR2 appear to play multiple roles in the physiologies and pathologies of the endometrium. They are also suggested to play important functions in the pathogenesis and pathophysiology of endometriosis. Therefore, it is expected to modulate the endometrial function and treat endometriosis by regulating the expression and the function of PAR1 and PAR2. Stated differently, the PARs themselves, their activating serine proteinases and their associated signaling pathways can be considered as attractive target for therapeutic drug development. In this context, it is remarkable that several agonists and antagonists for PAR1 and PAR2 have been developed (113) and an oral PAR1 antagonist is under clinical trial for the treatment and prevention of atherothrombosis (114). It is thus warranted to study more on PARs in the endometrium and endometriosis in order to find PAR targeting therapies as well as to understand the mechanism of the disease.
6. ACKNOWLEDGEMENT
This work is partly supported by grants from the Ministry of Health, Labour and Welfare, and the Ministry of Education, Culture, Sports, Science and Technology.
7. REFERENCES
1.Coughlin S.R.: Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost 3, 1800-1814 (2005)
doi:10.1111/j.1538-7836.2005.01377.x
2. Hollenberg M.D., S.J. Compton: International Union of Pharmacology. XXVIII. Proteinase-activated receptors. Pharmacol Rev 54, 203-17 (2002)
doi:10.1124/pr.54.2.203
3. Kawabata A., R. Kuroda: Protease-activated receptor (PAR), a novel family of G protein-coupled seven trans-membrane domain receptors: activation mechanisms and physiological roles. Jpn J Pharmacol 82, 171-4 (2000)
doi:10.1254/jjp.82.171
4. Ossovskaya V.S., N.W. Bunnett: Protease-Activated Receptors: Contribution to Physiology and Disease. Physiol Rev 84, 579-621 (2004)
doi:10.1152/physrev.00028.2003
5. Soh U.J., M.R. Dores, B. Chen, J. Trejo: Signal transduction by protease-activated receptors. Br J Pharmacol 160, 191-203 (2010)
doi:10.1111/j.1476-5381.2010.00705.x
6. Gerszten R.E., J. Chen, M. Ishli, K. Ishil, L. Wang, T. Nanevicz, C.W. Turck, T.-K.H. Vu, S.R. Coughlin: Specificity of the thrombin receptor for agonist peptide is defined by its extracellular surface. Nature 368, 648-651 (1994)
doi:10.1038/368648a0
7. Hirota Y., Y. Osuga, T. Hirata, M. Harada, C. Morimoto, O. Yoshino, K. Koga, T. Yano, O. Tsutsumi, Y. Taketani: Activation of protease-activated receptor 2 stimulates proliferation and interleukin (IL)-6 and IL-8 secretion of endometriotic stromal cells. Hum Reprod 20, 3547-3553 (2005)
doi:10.1093/humrep/dei255
8. Lo H.M., C.L. Chen, Y.J. Tsai, P.H. Wu, W.B. Wu: Thrombin induces cyclooxygenase-2 expression and prostaglandin E2 release via PAR1 activation and ERK1/2- and p38 MAPK-dependent pathway in murine macrophages. J Cell Biochem 108, 1143-1152 (2009)
doi:10.1002/jcb.22341
9. Coughlin S.R.: Thrombin signalling and protease-activated receptors. Nature 407, 258-264 (2000)
doi:10.1038/35025229
10. Riewald M., W. Ruf: Science review: role of coagulation protease cascades in sepsis. Crit Care 7, 123-9 (2003)
doi:10.1186/cc1825
11. Camerer E., W. Huang, S.R. Coughlin: Tissue factor- and factor X-dependent activation of protease-activated receptor 2 by factor VIIa. Proc Natl Acad Sci USA 97, 5255-5260 (2000)
doi:10.1073/pnas.97.10.5255
12. Riewald M., W. Ruf: Mechanistic coupling of protease signaling and initiation of coagulation by tissue factor. Proc Natl Acad Sci USA 98, 7742-7747 (2001)
doi:10.1073/pnas.141126698
13. Ahamed J., H.H. Versteeg, M. Kerver, V.M. Chen, B.M. Mueller, P.J. Hogg, W. Ruf: Disulfide isomerization switches tissue factor from coagulation to cell signaling. Proc Natl Acad Sci USA 103, 13932-13937 (2006)
doi:10.1073/pnas.0606411103
14. GH C.: Mast cell chymases and tryptases: phylogeny, family relations, and biogenesis. In: Mast Cell Proteases in Immunology and Biology. Ed C. GH. Dekker, New York (1995)
15. Salamonsen L.A.: Tissue injury and repair in the female human reproductive tract. Reproduction 125, 301-11 (2003)
doi:10.1530/rep.0.1250301
16. Lockwood C., Y. Nemerson, S. Guller, G. Krikun, M. Alvarez, V. Hausknecht, E. Gurpide, F. Schatz: Progestational regulation of human endometrial stromal cell tissue factor expression during decidualization. J Clin Endocrinol Metab 76, 231-236 (1993)
doi:10.1210/jc.76.1.231
17. Lockwood C.J., G. Krikun, C. Papp, E. Toth, L. Markiewicz, E.Y. Wang, T. Kerenyi, X. Zhou, V. Hausknecht, Z. Papp, F. Schatz: The Role of Progestationally Regulated Stromal Cell Tissue Factor and Type-1 Plasminogen Activator Inhibitor (PAI-1) in Endometrial Hemostasis and Menstruation. Ann N Y Acad Sci 734, 57-79 (1994)
doi:10.1111/j.1749-6632.1994.tb21736.x
18. Runic R., F. Schatz, L. Krey, R. Demopoulos, S. Thung, L. Wan, C.J. Lockwood: Alterations in Endometrial Stromal Cell Tissue Factor Protein and Messenger Ribonucleic Acid Expression in Patients Experiencing Abnormal Uterine Bleeding While Using Norplant-2 Contraception. J Clin Endocrinol Metab 82, 1983-1988 (1997)
doi:10.1210/jc.82.6.1983
19. Smith S.K.: Regulation of angiogenesis in the endometrium. Trends Endocrinol Metab 12, 147-151 (2001)
doi:10.1016/S1043-2760(01)00379-4
20. Girling J., P. Rogers: Recent advances in endometrial angiogenesis research. Angiogenesis 8, 89-99 (2005)
doi:10.1007/s10456-005-9006-9
21. Smith S.: Angiogenesis, vascular endothelial growth factor and the endometrium. Hum Reprod Update 4, 509-519 (1998)
doi:10.1093/humupd/4.5.509
22. Krikun G., F. Schatz, C.J. Lockwood: Endometrial Angiogenesis: From Physiology to Pathology. Ann N Y Acad Sci 1034, 27-35 (2004)
doi:10.1196/annals.1335.003
23. Sarker K.P., H. Yamahata, M. Nakata, T. Arisato, T. Nakajima, I. Kitajima, I. Maruyama: Recombinant Thrombomodulin Inhibits Thrombin-Induced Vascular Endothelial Growth Factor Production in Neuronal Cells. Pathophysiology of Haemostasis and Thrombosis 29, 343-352 (1999)
doi:10.1159/000022522
24. Huang Y.Q., J.J. Li, L. Hu, M. Lee, S. Karpatkin: Thrombin induces increased expression and secretion of VEGF from human FS4 fibroblasts, DU145 prostate cells and CHRF megakaryocytes. Thromb Haemost 86, 1094-8 (2001)
25. Bassus S., O. Herkert, N. Kronemann, A. Gorlach, D. Bremerich, C.M. Kirchmaier, R. Busse, V.B. Schini-Kerth: Thrombin Causes Vascular Endothelial Growth Factor Expression in Vascular Smooth Muscle Cells: Role of Reactive Oxygen Species. Arterioscler Thromb Vasc Biol 21, 1550-1555 (2001)
doi:10.1161/hq0901.095148
26. Lockwood C.J., G. Krikun, A.B.C. Koo, S. Kadner, F. Schatz: Differential Effects of Thrombin and Hypoxia on Endometrial Stromal and Glandular Epithelial Cell Vascular Endothelial Growth Factor Expression. J Clin Endocrinol Metab 87, 4280-4286 (2002)
doi:10.1210/jc.2001-011969
27. Tsopanoglou N.E., M.E. Maragoudakis: On the Mechanism of Thrombin-induced Angiogenesis. J Bioll Chem 274, 23969-23976 (1999)
doi:10.1074/jbc.274.34.23969
28. Ukropec J.A., M.K. Hollinger, S.M. Salva, M.J. Woolkalis: SHP2 Association with VE-Cadherin Complexes in Human Endothelial Cells Is Regulated by Thrombin. J Bioll Chem 275, 5983-5986 (2000)
doi:10.1074/jbc.275.8.5983
29. Esser S., M. Lampugnani, M. Corada, E. Dejana, W. Risau: Vascular endothelial growth factor induces VE-cadherin tyrosine phosphorylation in endothelial cells. J Cell Sci 111, 1853-1865 (1998)
30. Runic R., F. Schatz, L. Wan, R. Demopoulos, G. Krikun, C.J. Lockwood: Effects of Norplant on Endometrial Tissue Factor Expression and Blood Vessel Structure. J Clin Endocrinol Metab 85, 3853-3859 (2000)
doi:10.1210/jc.85.10.3853
31. Lau T.M., B. Affandi, P.A.W. Rogers: The effects of levonorgestrel implants on vascular endothelial growth factor expression in the endometrium. Mol Hum Reprod 5, 57-63 (1999)
doi:10.1093/molehr/5.1.57
32. Moses M.A., R. Langer: Inhibitors of Angiogenesis. Nat Biotech 9, 630-634 (1991)
doi:10.1038/nbt0791-630
33. Matrisian L.M.: The matrix-degrading metalloproteinases. BioEssays 14, 455-463 (1992)
doi:10.1002/bies.950140705
34. Woessner J.F., Jr.: The family of matrix metalloproteinases. Ann N Y Acad Sci 732, 11-21 (1994)
doi:10.1111/j.1749-6632.1994.tb24720.x
35. Binder B.R., G. Christ, F. Gruber, N. Grubic, P. Hufnagl, M. Krebs, J. Mihaly, G.W. Prager: Plasminogen Activator Inhibitor 1: Physiological and Pathophysiological Roles. News Physiol Sci 17, 56-61 (2002)
36. Lockwood C., G. Krikun, S. Aigner, F. Schatz: Effects of thrombin on steroid-modulated cultured endometrial stromal cell fibrinolytic potential. J Clin Endocrinol Metab 81, 107-112 (1996)
doi:10.1210/jc.81.1.107
37. Lockwood C., G. Krikun, C. Papp, S. Aigner, F. Schatz: Biological mechanisms underlying the clinical effects of RU 486: modulation of cultured endometrial stromal cell plasminogen activator and plasminogen activator inhibitor expression. J Clin Endocrinol Metab 80, 1100-1105 (1995)
doi:10.1210/jc.80.4.1100
38. Jeziorska M., L.A. Salamonsen, D.E. Woolley: Mast cell and eosinophil distribution and activation in human endometrium throughout the menstrual cycle. Biol Reprod 53, 312-320 (1995)
doi:10.1095/biolreprod53.2.312
39. Hirota Y., Y. Osuga, T. Hirata, K. Koga, O. Yoshino, M. Harada, C. Morimoto, E. Nose, T. Yano, O. Tsutsumi, Y. Taketani: Evidence for the presence of protease-activated receptor 2 and its possible implication in remodeling of human endometrium. J Clin Endocrinol Metab 90, 1662-9 (2005)
doi:10.1210/jc.2004-0726
40. Arici A., E. Seli, H.B. Zeyneloglu, L.M. Senturk, E. Oral, D.L. Olive: Interleukin-8 Induces Proliferation of Endometrial Stromal Cells: a Potential Autocrine Growth Factor. J Clin Endocrinol Metab 83, 1201-1205 (1998)
doi:10.1210/jc.83.4.1201
41. Iwabe T., T. Harada, T. Tsudo, M. Tanikawa, Y. Onohara, N. Terakawa: Pathogenetic Significance of Increased Levels of Interleukin-8 in the Peritoneal Fluid of Patients with Endometriosis. Fertil Steril 69, 924-930 (1998)
doi:10.1016/S0015-0282(98)00049-1
42. Arici A., E. Seli, L.M. Senturk, L.S. Gutierrez, E. Oral, H.S. Taylor: Interleukin-8 in the Human Endometrium. J Clin Endocrinol Metab 83, 1783-1787 (1998)
doi:10.1210/jc.83.5.1783
43. Milne S.A., H.O.D. Critchley, T.A. Drudy, R.W. Kelly, D.T. Baird: Perivascular Interleukin-8 Messenger Ribonucleic Acid Expression in Human Endometrium Varies across the Menstrual Cycle and in Early Pregnancy Decidua. J Clin Endocrinol Metab 84, 2563-2567 (1999)
doi:10.1210/jc.84.7.2563
44. Jones R.L., R.W. Kelly, H.O. Critchley: Chemokine and cyclooxygenase-2 expression in human endometrium coincides with leukocyte accumulation. Hum Reprod 12, 1300-1306 (1997)
doi:10.1093/humrep/12.6.1300
45. Kayisli U.A., N.G. Mahutte, A. Arici: Uterine Chemokines in Reproductive Physiology and Pathology. Am J Reprod Immunol 47, 213-221 (2002)
doi:10.1034/j.1600-0897.2002.01075.x
46. Mulayim N., A. Savlu, O. Guzeloglu-Kayisli, U.A. Kayisli, A. Arici: Regulation of endometrial stromal cell matrix metalloproteinase activity and invasiveness by interleukin-8. Fertil Steril 81, 904-911 (2004)
doi:10.1016/j.fertnstert.2003.11.015
47. Garcia-Velasco J.A., A. Arici: Interleukin-8 stimulates the adhesion of endometrial stromal cells to fibronectin. Fertil Steril 72, 336-340 (1999)
doi:10.1016/S0015-0282(99)00223-X
48. Mulayim N., A. Savlu, A. Arici: Interleukin-8 Increases Endometrial Stromal Cell Metalloproteinase Activity: Possible Role in Endometriosis. Fertil Steril 74, S22-S22 (2000)
doi:10.1016/S0015-0282(00)00784-6
49. Okayama Y., T. Kawakami: Development, migration, and survival of mast cells. Immunol Res 34, 97-115 (2006)
doi:10.1385/IR:34:2:97
50. Zhang J., G. Nie, W. Jian, D.E. Woolley, L.A. Salamonsen: Mast Cell Regulation of Human Endometrial Matrix Metalloproteinases: A Mechanism Underlying Menstruation. Biol Reprod 59, 693-703 (1998)
doi:10.1095/biolreprod59.3.693
51. Wilson C.L., L.M. Matrisian: Matrilysin: An epithelial matrix metalloproteinase with potentially novel functions. Int J Biochem Cell Biol 28, 123-136 (1996)
doi:10.1016/1357-2725(95)00121-2
52. Rodgers W.H., K.G. Osteen, L.M. Matrisian, M. Navre, L.C. Giudice, F. Gorstein: Expression and localization of matrilysin, a matrix metalloproteinase, in human endometrium during the reproductive cycle. Am J Obstet Gynecol 168, 253-60 (1993)
53. Belham C.M., R.J. Tate, P.H. Scott, A.D. Pemberton, H.R. Miller, R.M. Wadsworth, G.W. Gould, R. Plevin: Trypsin stimulates proteinase-activated receptor-2-dependent and -independent activation of mitogen-activated protein kinases. Biochem J 320, 939-946 (1996)
54. Temkin V., B. Kantor, V. Weg, M.-L. Hartman, F. Levi-Schaffer: Tryptase Activates the Mitogen-Activated Protein Kinase/Activator Protein-1 Pathway in Human Peripheral Blood Eosinophils, Causing Cytokine Production and Release. J Immunol 169, 2662-2669 (2002)
55. Sabri A., G. Muske, H. Zhang, E. Pak, A. Darrow, P. Andrade-Gordon, S.F. Steinberg: Signaling Properties and Functions of Two Distinct Cardiomyocyte Protease-Activated Receptors. Circ Res 86, 1054-1061 (2000)
56. Momoeda M., Y. Taketani, N. Terakawa, H. Hoshiai, K. Tanaka, O. Tsutsumi, Y. Osuga, M. Maruyama, T. Harada, K. Obata, K. Hayashi: Is endometriosis really associated with pain? Gynecol Obstet Invest 54 Suppl 1, 18-21; discussion 21-3 (2002)
doi:10.1159/000066290
57. Osuga Y., K. Koga, O. Tsutsumi, T. Yano, M. Maruyama, K. Kugu, M. Momoeda, Y. Taketani: Role of laparoscopy in the treatment of endometriosis-associated infertility. Gynecol Obstet Invest 53 Suppl 1, 33-9 (2002)
doi:10.1159/000049422
58. Sampson J.: Peritoneal endometriosis due to the menstrual dissemination of endometrial tissue into the peritoneal cavity. Am J Obstet Gynecol 14, 422-469 (1927)
59. ISAACSON K.B., C. COUTIFARIS, C.-R. GARCIA, C.R. LYTTLE: Production and Secretion of Complement Component 3 by Endometriotic Tissue. J Clin Endocrinol Metab 69, 1003-1009 (1989)
doi:10.1210/jcem-69-5-1003
60. Osuga Y., K. Koga, O. Tsutsumi, T. Igarashi, R. Okagaki, Y. Takai, H. Matsumi, H. Hiroi, T. Fujiwara, M. Momoeda, T. Yano, Y. Taketani: Stem cell factor (SCF) concentrations in peritoneal fluid of women with or without endometriosis. Am J Reprod Immunol 44, 231-5 (2000)
doi:10.1111/j.8755-8920.2000.440407.x
61. Taketani Y., T.M. Kuo, M. Mizuno: Comparison of cytokine levels and embryo toxicity in peritoneal fluid in infertile women with untreated or treated endometriosis. Am J Obstet Gynecol 167, 265-70 (1992)
62. Vernon M.W., J.S. Beard, K. Graves, E.A. Wilson: Classification of endometriotic implants by morphologic appearance and capacity to synthesize prostaglandin F. Fertil Steril 46, 801-6 (1986)
63. Halme J., S. Becker, M.G. Hammond, M.H.G. Raj, S. Raj: Increased activation of pelvic macrophages in infertile women with mild endometriosis. Am J Obstet Gynecol 145, 333-337 (1983)
64. Hill J.A., H.M.P. Faris, I. Schiff, D.J. Anderson: Characterization of leukocyte subpopulations in the peritoneal-fluid of women with endometriosis. Fertil Steril 50, 216-222 (1988)
65. Akoum A., C. Lawson, S. McColl, M. Villeneuve: Ectopic endometrial cells express high concentrations of interleukin (IL)-8 in vivo regardless of the menstrual cycle phase and respond to oestradiol by up-regulating IL-1-induced IL-8 expression in vitro. Mol Hum Reprod 7, 859-866 (2001)
doi:10.1093/molehr/7.9.859
66. Akoum A., A. Lemay, R. Maheux: Estradiol and interleukin-1 beta exert a synergistic stimulatory effect on the expression of the chemokine regulated upon activation, normal T cell expressed, and secreted in endometriotic cells. J Clin Endocrinol Metab 87, 5785-5792 (2002)
doi:10.1210/jc.2002-020106
67. Klein N.A., G.M. Pergola, R.R. Tekmal, I.A. Montoya, T.D. Dey, R.S. Schenken: Cytokine regulation of cellular proliferation in endometriosis. In: Human Endometrium. Ed C. Bulletti, E. Gurpide&C. Flamigni. New York Acad Sciences, New York (1994)
68. Halme J.: Role of Peritoneal Inflammation in Endometriosis-associated Infertility. Ann N Y Acad Sci 622, 266-274 (1991)
doi:10.1111/j.1749-6632.1991.tb37870.x
69. Wu M.Y., H.N. Ho: The role of cytokines in endometriosis. Am J Reprod Immunol 49, 285-296 (2003)
doi:10.1034/j.1600-0897.2003.01207.x
70. Lebovic D.I., M.D. Mueller, R.N. Taylor: Immunobiology of endometriosis. Fertil Steril 75, 1-10 (2001)
doi:10.1016/S0015-0282(00)01630-7
71. Hirota Y., Y. Osuga, T. Hirata, O. Yoshino, K. Koga, M. Harada, C. Morimoto, E. Nose, T. Yano, O. Tsutsumi, Y. Taketani: Possible involvement of thrombin/protease-activated receptor 1 system in the pathogenesis of endometriosis. J Clin Endocrinol Metab 90, 3673-9 (2005)
doi:10.1210/jc.2004-0493
73. Vasquez G., F. Cornillie, I.A. Brosens: Peritoneal endometriosis: scanning electron microscopy and histology of minimal pelvic endometriotic lesions. Fertil Steril 42, 696-703 (1984)
74. Sampson J.: Perforating hemorrhagic (chocolate) cysts of the ovary. Arch Surg 3, 245-323 (1921)
75. Metzger D.A., D.L. Olive, A.F. Haney: Limited hormonal responsiveness of ectopic endometrium: Histologic correlation with intrauterine endometrium. Hum Pathol 19, 1417-1424 (1988)
doi:10.1016/S0046-8177(88)80234-X
76. Akoum A., A. Lemay, S. McColl, L. TurcotLemay, R. Maheux: Elevated concentration and biologic activity of monocyte chemotactic protein-1 in the peritoneal fluid of patients with endometriosis. Fertil Steril 66, 17-23 (1996)
77. Ryan I.P., J.F. Tseng, E.D. Schriock, O. Khorram, D.V. Landers, R.N. Taylor: Interleukin-8 concentrations are elevated in peritoneal-fluid of women with endometriosis. Fertil Steril 63, 929-932 (1995)
78. Akoum A., C. Jolicoeur, A. Boucher: Estradiol amplifies interleukin-1-induced monocyte chemotactic protein-1 expression by ectopic endometrial cells of women with endometriosis. J Clin Endocrinol Metab 85, 896-904 (2000)
doi:10.1210/jc.85.2.896
79. Jolicoeur C., M. Boutouil, R. Drouin, I. Paradis, A. Lemay, A. Akoum: Increased expression of monocyte chemotactic protein-1 in the endometrium of women with endometriosis. Am J Pathol 152, 125-133 (1998)
80. Harada T., T. Iwabe, N. Terakawa: Role of cytokines in endometriosis. Fertil Steril 76, 1-10 (2001)
doi:10.1016/S0015-0282(01)01816-7
81. Arici A.: Local Cytokines in Endometrial Tissue: The Role of Interleukin-8 in the Pathogenesis of Endometriosis. Ann N Y Acad Sci 955, 101-109 (2002)
doi:10.1111/j.1749-6632.2002.tb02770.x
82. Bulun S.E.: Endometriosis. New Eng J Med 360, 268-279 (2009)
doi:10.1056/NEJMra0804690
83. Krikun G., F. Schatz, H. Taylor, C.J. Lockwood: Endometriosis and Tissue Factor. Ann N Y Acad Sci 1127, 101-105 (2008)
doi:10.1196/annals.1434.008
83. Nguyen M., J. Arkell, C.J. Jackson: Human endothelial gelatinases and angiogenesis. Int J Biochem Cell Biol 33, 960-970 (2001)
doi:10.1016/S1357-2725(01)00007-3
84. Pekovich S.R., P.E. Bock, R.L. Hoover: Thrombin-thrombomodulin activation of protein C facilitates the activation of progelatinase A. Febs Lett 494, 129-132 (2001)
doi:10.1016/S0014-5793(01)02296-7
85. Wenzl R.J., H. Heinzl: Localization of matrix metalloproteinase-2 in uterine endometrium and ectopic implants. Gynecol Obstet Invest 45, 253-257 (1998)
doi:10.1159/000009978
86. Ria R., G. Loverro, A. Vacca, D. Ribatti, G. Cormio, A.M. Roccaro, L. Selvaggi: Angiogenesis extent and expression of matrix metalloproteinase-2 and-9 agree with progression of ovarian endometriomas. Eur J Clin Invest 32, 199-206 (2002)
doi:10.1046/j.1365-2362.2002.00960.x
87. Derian C.K., B.P. Damiano, M.F. Addo, A.L. Darrow, M.R. D'Andrea, M. Nedelman, H.-C. Zhang, B.E. Maryanoff, P. Andrade-Gordon: Blockade of the thrombin receptor protease-activated receptor-1 with a small-molecule antagonist prevents thrombus formation and vascular occlusion in nonhuman primates. J Pharmacol Exp Ther 304, 855-861 (2003)
doi:10.1124/jpet.102.042663
88. Chackalamannil S.: G-protein coupled receptor antagonists-1: protease activated receptor-1 (PAR-1) antagonists as novel cardiovascular therapeutic agents. Curr Top Med Chem 3, 1115-23 (2003)
doi:10.2174/1568026033452122
89. Matsuzaki S., M. Canis, C. Darcha, T. Fukaya, A. Yajima, M.A. Bruhat: Increased mast cell density in peritoneal endometriosis compared with eutopic endometrium with endometriosis. Am J Reprod Immunol 40, 291-4 (1998)
90. Sugamata M., T. Ihara, I. Uchiide: Increase of Activated Mast Cells in Human Endometriosis. Am J Reprod Immunol 53, 120-125 (2005)
doi:10.1111/j.1600-0897.2005.00254.x
91. Fujiwara H., R. Konno, S. Netsu, M. Sugamata, H. Shibahara, M. Ohwada, M. Suzuki: Localization of Mast Cells in Endometrial Cysts. Am J Reprod Immunol 51, 341-344 (2004)
doi:10.1111/j.1600-0897.2004.00166.x
92. Anaf V., C. Chapron, I. El Nakadi, V. De Moor, T. Simonart, J.-C. No・: Pain, mast cells, and nerves in peritoneal, ovarian, and deep infiltrating endometriosis. Fertil Steril 86, 1336-1343 (2006)
doi:10.1016/j.fertnstert.2006.03.057
93. Nichols T.R., K. Lamb, J.A. Arkins: The association of atopic diseases with endometriosis. Ann Allergy 59, 360-3 (1987)
94. Ferrero S., P. Petrera, B.M. Colombo, R. Navaratnarajah, M. Parisi, P. Anserini, V. Remorgida, N. Ragni: Asthma in women with endometriosis. Hum Reprod 20, 3514-3517 (2005)
doi:10.1093/humrep/dei263
95. Kempuraj D., N. Papadopoulou, E.J. Stanford, S. Christodoulou, B. Madhappan, G.R. Sant, K. Solage, T. Adams, T.C. Theoharides: Increased Numbers of Activated Mast Cells in Endometriosis Lesions Positive for Corticotropin-Releasing Hormone and Urocortin. Am J Reprod Immunol 52, 267-275 (2004)
doi:10.1111/j.1600-0897.2004.00224.x
96. Konno R., H. Yamada-Okabe, H. Fujiwara, I. Uchiide, H. Shibahara, M. Ohwada, T. Ihara, M. Sugamata, M. Suzuki: Role of immunoreactions and mast cells in pathogenesis of human endometriosis -morphologic study and gene expression analysis. Hum Cell 16, 141-149 (2003)
doi:10.1111/j.1749-0774.2003.tb00146.x
97. Uchiide I., T. Ihara, M. Sugamata: Pathological evaluation of the rat endometriosis model. Fertil Steril 78, 782-786 (2002)
doi:10.1016/S0015-0282(02)03327-7
98. Ihara T., I. Uchiide, M. Sugamata: Light and electron microscopic evaluation of antileukotriene therapy for experimental rat endometriosis. Fertil Steril 81, 819-823 (2004)
doi:10.1016/j.fertnstert.2003.08.029
99. Liu T., N. van Rooijen, D.J. Tracey: Depletion of macrophages reduces axonal degeneration and hyperalgesia following nerve injury. Pain 86, 25-32 (2000)
doi:10.1016/S0304-3959(99)00306-1
100. Zuo Y., N.M. Perkins, D.J. Tracey, C.L. Geczy: Inflammation and hyperalgesia induced by nerve injury in the rat: a key role of mast cells. Pain 105, 467-479 (2003)
doi:10.1016/S0304-3959(03)00261-6
101. Witz C.A.: Interleukin-6: another piece of the endometriosis-cytokine puzzle. Fertil Steril 73, 212-4 (2000)
doi:10.1016/S0015-0282(99)00556-7
102. Salmassi A., Y. Acil, A.G. Schmutzler, K. Koch, W. Jonat, L. Mettler: Differential interleukin-6 messenger ribonucleic acid expression and its distribution pattern in eutopic and ectopic endometrium. Fertil Steril 89, 1578-84 (2008)
doi:10.1016/j.fertnstert.2007.06.060
103. Velasco I., P. Acien, A. Campos, M.I. Acien, E. Ruiz-Macia: Interleukin-6 and other soluble factors in peritoneal fluid and endometriomas and their relation to pain and aromatase expression. J Reprod Immunol 84, 199-205 (2010)
doi:10.1016/j.jri.2009.11.004
104. Khan K.N., H. Masuzaki, A. Fujishita, M. Kitajima, K. Hiraki, I. Sekine, T. Matsuyama, T. Ishimaru: Interleukin-6- and tumour necrosis factor alpha-mediated expression of hepatocyte growth factor by stromal cells and its involvement in the growth of endometriosis. Hum Reprod 20, 2715-23 (2005)
doi:10.1093/humrep/dei156
105. Velasco I., J. Rueda, P. Acien: Aromatase expression in endometriotic tissues and cell cultures of patients with endometriosis. Mol Hum Reprod 12, 377-81 (2006)
doi:10.1093/molehr/gal041
106. Piva M., G.M. Horowitz, K.L. Sharpe-Timms: Interleukin-6 differentially stimulates haptoglobin production by peritoneal and endometriotic cells in vitro: a model for endometrial-peritoneal interaction in endometriosis. J Clin Endocrinol Metab 86, 2553-61 (2001)
doi:10.1210/jc.86.6.2553
107. Sharpe-Timms K.L., H. Nabli, R.L. Zimmer, J.A. Birt, J.W. Davis: Inflammatory cytokines differentially up-regulate human endometrial haptoglobin production in women with endometriosis. Hum Reprod 25, 1241-50 (2010)
doi:10.1093/humrep/deq032
108. Grümmer R.: Animal models in endometriosis research. Hum Reprod Update 12, 641-649 (2006)
doi:10.1093/humupd/dml026
109. Osuga Y., Y. Hirota, Y. Taketani: Basic and translational research on proteinase-activated receptors: proteinase-activated receptors in female reproductive tissues and endometriosis. J Pharmacol Sci 108, 422-5 (2008)
doi:10.1254/jphs.08R13FM
110. Yoshino O., Y. Osuga, K. Koga, Y. Hirota, T. Hirata, X. Ruimeng, L. Na, T. Yano, O. Tsutsumi, Y. Taketani: FR 167653, a p38 mitogen-activated protein kinase inhibitor, suppresses the development of endometriosis in a murine model. J Reprod Immunol 72, 85-93 (2006)
doi:10.1016/j.jri.2005.02.004
111. Hirata T., Y. Osuga, O. Yoshino, Y. Hirota, M. Harada, Y. Takemura, C. Morimoto, K. Koga, T. Yano, O. Tsutsumi, Y. Taketani: Development of an experimental model of endometriosis using mice that ubiquitously express green fluorescent protein. Hum Reprod 20, 2092-6 (2005)
doi:10.1093/humrep/dei012
112. Hasegawa A., O. Yoshino, Y. Osuga, A. Kodama, M. Takamura, O. Nishii, Y. Taketani: Hyaluronic acid reagent suppressed endometriotic lesion formation in a mouse model. Fertil Steril 93, 2757-9 (2010)
doi:10.1016/j.fertnstert.2010.02.053
113. Ramachandran R., M.D. Hollenberg: Proteinases and signalling: pathophysiological and therapeutic implications via PARs and more. Br J Pharmacol 153 Suppl 1, S263-82 (2008)
doi:10.1038/sj.bjp.0707507
114. Oestreich J.: SCH-530348, a thrombin receptor (PAR-1) antagonist for the prevention and treatment of atherothrombosis. Curr Opin Investig Drugs 10, 988-96 (2009)
Key Words: Endometrium, Endometriosis, Proteinase-activated receptor, Review
Send correspondence to: Yutaka Osuga, Department of Obstetrics and Gynecology, Faculty of Medicine, University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan, Tel: 81-3-3815-5411, Fax: 81-3-3816-2017, E-mail:yutakaos-tky@umin.ac.jp